Allergic response pathway

The allergic response pathway, widely recognized as Type I hypersensitivity, is a sophisticated biological cascade that mediates the immune system's overreaction to innocuous environmental antigens [3, 5]. The process typically involves an initial sensitization phase where the exposure to an allergen induces the production of allergen-specific immunoglobulin E (IgE) antibodies, which then bind to high-affinity FcεRI receptors on mast cells and basophils [6, 11]. Upon subsequent re-exposure, the allergen cross-links the IgE molecules, triggering the immediate release of inflammatory mediators like histamine and leukotrienes, which lead to acute symptoms such as vasodilation, increased vascular permeability, and bronchoconstriction [5, 8]. This is followed by a late-phase response characterized by the recruitment of Th2 lymphocytes and eosinophils, driven by a specific cytokine profile including IL-4, IL-5, and IL-13 [1, 9]. Therapeutic strategies aim to modulate this pathway by targeting specific signaling nodes, such as IgE, interleukin receptors, or the alarmins like TSLP that initiate the cascade [2, 13, 14].

Other names

Type I hypersensitivityTh2-mediated allergic responseIgE-mediated allergic cascadeAtopic response pathway

Pharmacological interventions targeting the allergic response pathway operate by neutralizing key molecular mediators or blocking their receptors to interrupt the inflammatory cascade. Monoclonal antibodies bind to free IgE to prevent its interaction with mast cell receptors, while others inhibit specific cytokines like IL-4, IL-5, or IL-13 to suppress the Th2-driven late-phase response. Antihistamines act as inverse agonists at H1 receptors to block the physiological effects of histamine release, and bronchodilators or epinephrine provide acute symptom relief by counteracting smooth muscle contraction and vasodilation.